Short Interest in Enzolytics, Inc. (OTCMKTS:ENZC) Decreases By 99.5%

Enzolytics, Inc. (OTCMKTS:ENZC) saw a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 1,874 shares, a decline of 99.5% from the February 12th total of 412,513 shares. Based on an average daily trading volume, of 16,015,665 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 16,015,665 shares, the short-interest ratio is currently 0.0 days.

Enzolytics Trading Down 25.0%

Shares of Enzolytics stock opened at $0.00 on Thursday. Enzolytics has a 12-month low of $0.00 and a 12-month high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.